FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282869> ?p ?o ?g. }

• W4379282869 endingPage "3145" @default.
• W4379282869 startingPage "3145" @default.
• W4379282869 abstract "3145 Background: Live biotherapeutic products (LBPs) are emerging novel anti-cancer therapies. MRx0518 is a gut microbiome-derived oral LBP, consisting of a single strain of Enterococcus gallinarum, which has demonstrated potent anti-tumorigenic efficacy pre-clinically. We have previously shown MRx0518 monotherapy is associated with significant genomic, immune, microbiome, and metabolomic changes, consistent with anti-cancer efficacy in treatment-naïve patients. Here, we report long-term subject follow-up, and further signals of immune modulatory changes from flow cytometry analysis. Methods: NCT03934827 is a Phase 1B single-centre study in treatment-naive patients with confirmed cancer, planned for surgical resection. 17 patients (8 breast, 4 prostate, 3 uterine, 1 bladder & 1 melanoma) received MRx0518 (1x10 10 -1x10 11 CFU) BID monotherapy for 7-28 days from inclusion until surgery. Safety data was collected from dosing until 1-year following cessation. Exploratory analysis included evaluation of pre- and post-treatment peripheral blood mononuclear cells (PBMCs) by multiparametric flow cytometry for leucocyte activation, indicative of anti-cancer efficacy. Results: A total of 29 adverse events (AEs), all CTCAE grade 1 (96%) and grade 2 (4%), were reported. Only 8 (28%) were deemed related to MRx0518. No grade 3/4 toxicities or serious AEs were recorded. At 30-days, and 1-year follow-up no further serious AEs occurred. At a median follow-up of 41 months, 13 (76%) patients remain cancer-free, with 2 (11%) reoccurrences and 2 (11%) lost to follow-up. Analysis of pre- and post-treatment PBMCs identified statistically significant increases in CD3 + CD56 + (p<0.0005), natural killer cells (p<0.005), natural killer T-cells (p<0.01), CD8 + CD62L + (p<0.001), and CD4 + CD62L + (p<0.0001) subsets following MRx0518 therapy. A positive trend was also seen in CD3 + CD8 + cells. Furthermore, we observed a significant increase in both subsets of T-regulatory lymphocytes (nTreg (p<0.05) and eTreg (p<0.05)) and a decrease in both CD4 + (p<0.05) and CD8 + (p<0.005) central memory cells. Sub-analysis of the breast cancer patient group showed a significantly higher increase in CD3 + CD56 + cells (p<0.0001) and intermediate monocytes (p<0.01). Conclusions: This study demonstrates the long-term safety profile of MRx0518 therapy in treatment-naïve cancer patients. Analysis of PBMCs reveals clear evidence of immune modulation, consistent with significant anti-cancer efficacy. This is concordant with prior findings from this study. Notably, significant changes in CD3 + CD56 + have also been demonstrated in other studies of microbiome modulation (e.g., NCT03341143), and may be important determinant of anti-cancer efficacy. Despite the limitations of a small sample size, this effect is particularly prominent in the breast cancer subgroup, warranting further evaluation. Clinical trial information: NCT03934827 ." @default.
• W4379282869 created "2023-06-05" @default.
• W4379282869 creator A5004197958 @default.
• W4379282869 creator A5006958187 @default.
• W4379282869 creator A5007279195 @default.
• W4379282869 creator A5012379431 @default.
• W4379282869 creator A5013582624 @default.
• W4379282869 creator A5023657314 @default.
• W4379282869 creator A5026569214 @default.
• W4379282869 creator A5028994376 @default.
• W4379282869 creator A5036232556 @default.
• W4379282869 creator A5043938082 @default.
• W4379282869 creator A5073139313 @default.
• W4379282869 creator A5073803926 @default.
• W4379282869 creator A5078407406 @default.
• W4379282869 creator A5079264223 @default.
• W4379282869 creator A5081747049 @default.
• W4379282869 creator A5091681745 @default.
• W4379282869 date "2023-06-01" @default.
• W4379282869 modified "2023-09-26" @default.
• W4379282869 title "Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naïve patients with cancer: Updated safety data." @default.
• W4379282869 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.3145" @default.
• W4379282869 hasPublicationYear "2023" @default.
• W4379282869 type Work @default.
• W4379282869 citedByCount "0" @default.
• W4379282869 crossrefType "journal-article" @default.
• W4379282869 hasAuthorship W4379282869A5004197958 @default.
• W4379282869 hasAuthorship W4379282869A5006958187 @default.
• W4379282869 hasAuthorship W4379282869A5007279195 @default.
• W4379282869 hasAuthorship W4379282869A5012379431 @default.
• W4379282869 hasAuthorship W4379282869A5013582624 @default.
• W4379282869 hasAuthorship W4379282869A5023657314 @default.
• W4379282869 hasAuthorship W4379282869A5026569214 @default.
• W4379282869 hasAuthorship W4379282869A5028994376 @default.
• W4379282869 hasAuthorship W4379282869A5036232556 @default.
• W4379282869 hasAuthorship W4379282869A5043938082 @default.
• W4379282869 hasAuthorship W4379282869A5073139313 @default.
• W4379282869 hasAuthorship W4379282869A5073803926 @default.
• W4379282869 hasAuthorship W4379282869A5078407406 @default.
• W4379282869 hasAuthorship W4379282869A5079264223 @default.
• W4379282869 hasAuthorship W4379282869A5081747049 @default.
• W4379282869 hasAuthorship W4379282869A5091681745 @default.
• W4379282869 hasConcept C121608353 @default.
• W4379282869 hasConcept C126322002 @default.
• W4379282869 hasConcept C137061746 @default.
• W4379282869 hasConcept C143998085 @default.
• W4379282869 hasConcept C185592680 @default.
• W4379282869 hasConcept C197934379 @default.
• W4379282869 hasConcept C202751555 @default.
• W4379282869 hasConcept C203014093 @default.
• W4379282869 hasConcept C2780192828 @default.
• W4379282869 hasConcept C526805850 @default.
• W4379282869 hasConcept C530470458 @default.
• W4379282869 hasConcept C553184892 @default.
• W4379282869 hasConcept C55493867 @default.
• W4379282869 hasConcept C71924100 @default.
• W4379282869 hasConcept C8891405 @default.
• W4379282869 hasConcept C90924648 @default.
• W4379282869 hasConceptScore W4379282869C121608353 @default.
• W4379282869 hasConceptScore W4379282869C126322002 @default.
• W4379282869 hasConceptScore W4379282869C137061746 @default.
• W4379282869 hasConceptScore W4379282869C143998085 @default.
• W4379282869 hasConceptScore W4379282869C185592680 @default.
• W4379282869 hasConceptScore W4379282869C197934379 @default.
• W4379282869 hasConceptScore W4379282869C202751555 @default.
• W4379282869 hasConceptScore W4379282869C203014093 @default.
• W4379282869 hasConceptScore W4379282869C2780192828 @default.
• W4379282869 hasConceptScore W4379282869C526805850 @default.
• W4379282869 hasConceptScore W4379282869C530470458 @default.
• W4379282869 hasConceptScore W4379282869C553184892 @default.
• W4379282869 hasConceptScore W4379282869C55493867 @default.
• W4379282869 hasConceptScore W4379282869C71924100 @default.
• W4379282869 hasConceptScore W4379282869C8891405 @default.
• W4379282869 hasConceptScore W4379282869C90924648 @default.
• W4379282869 hasFunder F4320320283 @default.
• W4379282869 hasIssue "16_suppl" @default.
• W4379282869 hasLocation W43792828691 @default.
• W4379282869 hasOpenAccess W4379282869 @default.
• W4379282869 hasPrimaryLocation W43792828691 @default.
• W4379282869 hasRelatedWork W2075214100 @default.
• W4379282869 hasRelatedWork W2224319365 @default.
• W4379282869 hasRelatedWork W2364051953 @default.
• W4379282869 hasRelatedWork W2381416288 @default.
• W4379282869 hasRelatedWork W2388808113 @default.
• W4379282869 hasRelatedWork W2392730113 @default.
• W4379282869 hasRelatedWork W2743631765 @default.
• W4379282869 hasRelatedWork W3004259476 @default.
• W4379282869 hasRelatedWork W377899687 @default.
• W4379282869 hasRelatedWork W4243514755 @default.
• W4379282869 hasVolume "41" @default.
• W4379282869 isParatext "false" @default.
• W4379282869 isRetracted "false" @default.
• W4379282869 workType "article" @default.